RxDoctor Payments Data

Kelly Rock

Psychiatric/Mental Health · Kittanning, PANPI 1164522942

Payments from drug & device makers

$962in general payments, 2019–2025

Across 59 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$218
  • Neurocrine Biosciences, Inc.$208
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132
  • Indivior Inc.$89
  • AbbVie$79
  • Alkermes, Inc.$77
  • plus $161 from 6 others

What the payments were for

  • Food & beverage$91595%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$962 in reported general payments places this provider in the 60th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$43,307
Medicare patients
69
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine25$161,002
Invega SustennaPaliperidone Palmitate33$81,208
Abilify MaintenaAripiprazole18$52,426
CaplytaLumateperone Tosylate13$22,033
VraylarCariprazine Hcl13$21,373
TrintellixVortioxetine Hydrobromide12$5,998
Vilazodone Hcl54$5,392
Lurasidone Hcl53$5,108
Paliperidone ErPaliperidone36$4,895
Aripiprazole65$4,144
Olanzapine103$3,485
Perphenazine16$2,029
Quetiapine Fumarate136$1,971
Duloxetine Hcl68$1,789
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl29$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$24$161,00225 claims
Johnson & JohnsonInvega Sustenna$23$81,20833 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$61$52,42618 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$132$22,03313 claims
AbbVieVraylar$79$21,37313 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$11$5,99812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Kittanning

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →